Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Gore

Showing results (31-40 of 215) with videos related to

Pageof 22
Sort By:
Cancer Journal (Sudbury, Mass.)|April 28, 2007
DNA demethylating agents and histone deacetylase inhibitors in hematologic malignanciesTamer E Fandy, Hetty Carraway, Steven D Gore
Leukemia & Lymphoma|January 21, 2003
Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemiaMuhammad Wasif Saif, Jon L Hopkins, Steven D Gore
Seminars in Hematology|June 27, 2015
Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future DirectionsTae Kon Kim, Steven D Gore, Amer M Zeidan
Current Opinion in Hematology|February 24, 2010
Novel approaches for myelodysplastic syndromes: beyond hypomethylating agentsArturo Loaiza-Bonilla, Steven D Gore, Hetty E Carraway
Expert Review of Hematology|June 21, 2013
Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?Amer M Zeidan, Steven D Gore, Rami S Komrokji
Expert Opinion on Investigational Drugs|January 26, 2016
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromesMaximilian Stahl, Steven D Gore, Norbert Vey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2017
US Food and Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the BoxAmer M Zeidan, Steven D Gore, Amy J Davidoff
Leukemia & Lymphoma|September 23, 2016
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomingsBrian Ball, Amer Zeidan, Steven D Gore, et al.
Expert Opinion on Pharmacotherapy|July 5, 2017
Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settingsNatalie Uy, Abhay Singh, Steven D Gore, et al.
The Oncologist|July 22, 2015
Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Aziz Nazha, Mikkael A Sekeres, Steven D Gore, et al.
Pageof 22

Showing results (31-40 of 215) with videos related to

Sort By:
Pageof 22
Cancer Journal (Sudbury, Mass.)|April 28, 2007
DNA demethylating agents and histone deacetylase inhibitors in hematologic malignanciesTamer E Fandy, Hetty Carraway, Steven D Gore
Leukemia & Lymphoma|January 21, 2003
Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemiaMuhammad Wasif Saif, Jon L Hopkins, Steven D Gore
Seminars in Hematology|June 27, 2015
Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future DirectionsTae Kon Kim, Steven D Gore, Amer M Zeidan
Current Opinion in Hematology|February 24, 2010
Novel approaches for myelodysplastic syndromes: beyond hypomethylating agentsArturo Loaiza-Bonilla, Steven D Gore, Hetty E Carraway
Expert Review of Hematology|June 21, 2013
Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?Amer M Zeidan, Steven D Gore, Rami S Komrokji
Expert Opinion on Investigational Drugs|January 26, 2016
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromesMaximilian Stahl, Steven D Gore, Norbert Vey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2017
US Food and Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the BoxAmer M Zeidan, Steven D Gore, Amy J Davidoff
Leukemia & Lymphoma|September 23, 2016
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomingsBrian Ball, Amer Zeidan, Steven D Gore, et al.
Expert Opinion on Pharmacotherapy|July 5, 2017
Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settingsNatalie Uy, Abhay Singh, Steven D Gore, et al.
The Oncologist|July 22, 2015
Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Aziz Nazha, Mikkael A Sekeres, Steven D Gore, et al.
Pageof 22